2 results
Approved WMOCompleted
We hypothesize that patients with a HER2-negative primary tumor but with at least one HER2-positive CTC benefit from HER2 targeted treatment with trastuzumab
Not applicableCompleted
Objective: The primary objective of the study is determining the contributing factors in bracing for AIS. The contributing factors are determined as factors of influence in the corrective possibilities and therefore end term…